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Introduction
Macrophage activation syndrome (MAS) is a severe,
potentially fatal complication of systemic juvenile idio-
pathic arthritis (sJIA). Changes in therapies, including
biologics, have been associated with the onset of MAS.
Interleukin-6 (IL-6) plays a major pathogenic role in
sJIA; data in animals suggest that high IL-6 levels con-
tribute to the triggering of MAS [1]. Treatment with the
IL-6 receptor inhibitor tocilizumab (TCZ) is highly
effective in patients with sJIA [2].
Objectives
To investigate the rates and features of MAS occurring
during TCZ treatment in patients with sJIA.
Methods
Data were collected from patients with sJIA treated with
TCZ in the international phase 3 trial (TENDER), 4 clini-
cal trials in Japan, and the Japanese postmarketing surveil-
lance (JPMS) program. Reported MAS events or disease
flares associated with alanine aminotransferase/aspartate
aminotransferase (ALT/AST) elevations were collected.
Worksheets with event information were assessed by an
independent panel (2 pediatric rheumatologists, 1 pediatric
hematologist with MAS expertise) overseen by the
TENDER lead investigator. Cases were adjudicated as defi-
nite MAS, potential MAS, not MAS, or insufficient data.
Results
The data set included 112 patients from TENDER
(403.0 patient-years’ [PY] exposure to TCZ), 149 patients
from the Japanese trials (326 PY), and 366 patients from
the JPMS program (523.9 PY). Of 31 cases reviewed, 22
events were adjudicated as definite or potential MAS: 5
from TENDER (3 definite, 2 potential), 6 from the
Japanese trials (3 definite, 3 potential), and 11 from the
JPMS program (5 definite, 6 potential). The rates/100
PY of definite/potential MAS were 1.24 (95% CI,
0.4-2.90) in TENDER, 1.84 (95% CI, 0.68-4.00) in the
Japanese trials, and 2.10 (95% CI, 1.05-3.76) in the JPMS
program. Laboratory and clinical features most com-
monly contributing to the adjudication of the 11 definite
MAS events were elevated ALT/AST in 11 (100%),
thrombocytopenia in 10 (91%), elevated ferritin in
8 (73%), leukopenia in 7 (64%), neutropenia in 6 (55%),
and fever in 6 (55%). All 11 events adjudicated as defi-
nite MAS met the preliminary MAS diagnostic guide-
lines [3]. All definite and potential MAS resolved, with
the exception of MAS in a patient from the Japanese
phase 3 study who died after respiratory/cardiac arrest.
Conclusion
The use of TCZ does not appear to be associated with
increased risk for MAS in sJIA. No unusual clinical or
laboratory features were observed in these MAS cases.
Disclosure of interest
F. De Benedetti Grant / Research Support from: Abbott,
Pfizer, BMS, Roche, Novimmune, Novartis, SOBI, R.
Schneider Consultant for: Roche, Novartis, S. Weitzman:
None declared., C. Devlin Employee of: Roche Products
Ltd., K. Daimaru Employee of: Chugai Pharmaceutical,
S. Yokota Consultant for: Chugai (includes royalties),
S. Takei Grant / Research Support from: BMS, Chugai,
Eisai, Takeda, Speaker Bureau of: Chugai, taisyo-Toyama,
1IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy
Full list of author information is available at the end of the article
De Benedetti et al. Pediatric Rheumatology 2014, 12(Suppl 1):P55
http://www.ped-rheum.com/content/12/S1/P55
© 2014 De Benedetti et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Japan Blood Products, Santen, Takeda, Eisai, A. Ravelli
Grant / Research Support from: Pfizer, Consultant for:
Roche, Speaker Bureau of: Pfizer, AbbVie, BMS, Novartis.
Authors’ details
1IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy. 2The Hospital for Sick
Children, Toronto, Canada. 3Roche Products Ltd., Welwyn Garden City, UK.
4Chugai Pharmaceutical, Tokyo. 5Yokohama City University School of
Medicine, Yokohama, Japan. 6School of Health Science, Faculty of Medicine,
Kagoshima University, Kagoshima, Japan. 7University of Genoa and Istituto
Giannina Gaslini, Genoa, Italy.
Published: 17 September 2014
References
1. Strippoli R, et al: Arthritis Rheum 2012, 64:1680-1688.
2. De Benedetti F, et al: N Engl J Med 2012, 367:2385.
3. Ravelli A, et al: J Pediatr 2005, 146:598-604.
doi:10.1186/1546-0096-12-S1-P55
Cite this article as: De Benedetti et al.: Macrophage activation syndrome
in patients with systemic juvenile idiopathic arthritis treated with
tocilizumab. Pediatric Rheumatology 2014 12(Suppl 1):P55.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
De Benedetti et al. Pediatric Rheumatology 2014, 12(Suppl 1):P55
http://www.ped-rheum.com/content/12/S1/P55
Page 2 of 2
